The Asia Pacific Narcolepsy Therapeutics Market is expected to witness market growth of 11.4% CAGR during the forecast period (2022-2028).
Narcoleptics have a strong want to sleep and are low on energy. Cataplexy is an abrupt loss of muscle tone and weakness that might last for a few seconds or several minutes. It frequently happens when under the stress of weariness; it is brought on by feelings like fear, laughing, or surprise. Temporarily being unable to move any portion of the body is the hallmark of sleep paralysis. Fear sets it off, but it has no negative effects. Narcoleptics may also hallucinate, which are characterized by vivid, frequently terrifying dreams.
Any mental disorder, a deficiency in the brain chemical hypocretin, hereditary conditions, infections, trauma, hormonal changes, stress, immune-system failure, etc. can all contribute to narcolepsy. A hereditary predisposition exists in around 10% of people who develop narcolepsy with cataplexy. Men and women of any age can develop narcolepsy, which can start in the early 20s and last the rest of their lives. In the United States, it is estimated that one person in every 2000 individuals has narcolepsy, and those who have it live regular lives.
It was conducted in the family medicine outpatient department at St. Philomena's Hospital, Bengaluru, as part of a cross-sectional study. Written consent was obtained from all adult patients visiting the outpatient department between September 1st and October 30th, 2015. They used the Athens Insomnia Scale to diagnose insomnia and gathered data on co-morbidities in medicine. To determine the prevalence of insomnia and its associated co-morbidities, examined the data.
The China market dominated the Asia Pacific Narcolepsy Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $432.8 million by 2028.The Japan market is estimated to grow a CAGR of 10.7% during (2022 - 2028). Additionally, The India market is expected to experience a CAGR of 12.1% during (2022 - 2028).
Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
Narcoleptics have a strong want to sleep and are low on energy. Cataplexy is an abrupt loss of muscle tone and weakness that might last for a few seconds or several minutes. It frequently happens when under the stress of weariness; it is brought on by feelings like fear, laughing, or surprise. Temporarily being unable to move any portion of the body is the hallmark of sleep paralysis. Fear sets it off, but it has no negative effects. Narcoleptics may also hallucinate, which are characterized by vivid, frequently terrifying dreams.
Any mental disorder, a deficiency in the brain chemical hypocretin, hereditary conditions, infections, trauma, hormonal changes, stress, immune-system failure, etc. can all contribute to narcolepsy. A hereditary predisposition exists in around 10% of people who develop narcolepsy with cataplexy. Men and women of any age can develop narcolepsy, which can start in the early 20s and last the rest of their lives. In the United States, it is estimated that one person in every 2000 individuals has narcolepsy, and those who have it live regular lives.
It was conducted in the family medicine outpatient department at St. Philomena's Hospital, Bengaluru, as part of a cross-sectional study. Written consent was obtained from all adult patients visiting the outpatient department between September 1st and October 30th, 2015. They used the Athens Insomnia Scale to diagnose insomnia and gathered data on co-morbidities in medicine. To determine the prevalence of insomnia and its associated co-morbidities, examined the data.
The China market dominated the Asia Pacific Narcolepsy Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $432.8 million by 2028.The Japan market is estimated to grow a CAGR of 10.7% during (2022 - 2028). Additionally, The India market is expected to experience a CAGR of 12.1% during (2022 - 2028).
Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type- Narcolepsy with Cataplexy
- Narcolepsy Without Cataplexy
- Secondary Narcolepsy
- Sodium Oxybate
- Selective Serotonin Reuptake Inhibitor
- Central Nervous System Stimulants
- Tricyclic Antidepressants
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Jazz Pharmaceuticals plc
- Shionogi & Co., Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
- Bioprojet
- Takeda Pharmaceutical Company Limited
- Ligand Pharmaceuticals, Inc.
- Graymark Healthcare, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Narcolepsy Therapeutics Market by Type
Chapter 4. Asia Pacific Narcolepsy Therapeutics Market by Product
Chapter 5. Asia Pacific Narcolepsy Therapeutics Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Jazz Pharmaceuticals plc
- Shionogi & Co., Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
- Bioprojet
- Takeda Pharmaceutical Company Limited
- Ligand Pharmaceuticals, Inc.
- Graymark Healthcare, Inc.
Methodology
LOADING...
